Allogene shareholders elect directors, approve authorized share increase to 400M

Allogene Therapeutics, Inc.

Four Class I directors elected: Elizabeth Barrett, Arie Belldegrun, David Bonderman, David Chang.
Advisory vote on executive compensation passed: 103,325,400 for, 7,596,094 against.
Authorized common shares increased from 200M to 400M; amendment filed June 16, 2022.
Stock option exchange program approved: 77,394,629 for, 33,536,201 against.
Ernst & Young ratified as auditor for FY2022: 125,514,754 for, 49,928 against.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.